arrow_back Civic Audit
Share share

Stop Drug Companies Blocking Cheaper Generics

This bill aims to lower drug costs by preventing pharmaceutical companies from interfering with doctors' decisions to prescribe cheaper generic or biosimilar drugs instead of expensive brand names. It stops companies from offering incentives or directing doctors to choose brand names when alternatives exist.
Key points
Drug companies cannot give doctors gifts or tell them to prescribe only brand-name drugs if a generic is available.
Doctors keep the freedom to choose the best drug for you based on medical judgment.
Government agencies and states can take legal action and fine companies that break these rules.
This could lead to more affordable prescription drug options for you.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_7473
Sponsor: Rep. Maloney, Carolyn B. [D-NY-12]
Process start date: 2022-04-07
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Generic Substitution Noninterference Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7473.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-04-07.

What are the main provisions?

Key points include:

  • Drug companies cannot give doctors gifts or tell them to prescribe only brand-name drugs if a generic is available.
  • Doctors keep the freedom to choose the best drug for you based on medical judgment.
  • Government agencies and states can take legal action and fine companies that break these rules.
  • This could lead to more affordable prescription drug options for you.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Maloney, Carolyn B. [D-NY-12].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Economy